Two Sigma Advisers
KPTI icon

Two Sigma Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Two Sigma Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-89,729
Closed -$660K – 1137
2025
Q4 		$660K Buy
+89,729
New +$549K ﹤0.01% 1674
2025
Q1 		– Sell
-5,107
Closed -$51.8K – 2489
2024
Q4 		$51.8K Buy
5,107
+3,027
+146% +$36.6K ﹤0.01% 2279
2024
Q3 		$25.9K Buy
+2,080
New +$25.8K ﹤0.01% 2244
2024
Q1 		– Sell
-4,213
Closed -$54.7K – 2553
2023
Q4 		$54.7K Buy
4,213
+1,866
+80% +$25.1K ﹤0.01% 2394
2023
Q3 		$47.2K Sell
2,347
-15,000
-86% -$337K ﹤0.01% 2280
2023
Q2 		$466K Sell
17,347
-9,420
-35% -$406K ﹤0.01% 1833
2023
Q1 		$1.56M Sell
26,767
-20,113
-43% -$993K ﹤0.01% 1402
2022
Q4 		$2.39M Sell
46,880
-8,540
-15% -$592K 0.01% 1138
2022
Q3 		$4.54M Sell
55,420
-10,313
-16% -$770K 0.01% 778
2022
Q2 		$4.45M Buy
65,733
+14,046
+27% +$1.29M 0.01% 827
2022
Q1 		$5.71M Buy
51,687
+23,180
+81% +$2.89M 0.02% 749
2021
Q4 		$2.75M Sell
28,507
-43,626
-60% -$4.35M 0.01% 1036
2021
Q3 		$6.3M Buy
72,133
+6,640
+10% +$689K 0.02% 688
2021
Q2 		$10.1M Buy
65,493
+4,813
+8% +$699K 0.03% 558
2021
Q1 		$9.57M Buy
60,680
+26,887
+80% +$5.67M 0.03% 589
2020
Q4 		$7.85M Sell
33,793
-45,267
-57% -$10.5M 0.02% 653
2020
Q3 		$17.3M Buy
79,060
+18,827
+31% +$4.61M 0.05% 358
2020
Q2 		$17.1M Buy
60,233
+11,426
+23% +$3.38M 0.05% 369
2020
Q1 		$14.1M Buy
48,807
+13,860
+40% +$3.82M 0.05% 375
2019
Q4 		$10M Buy
34,947
+21,380
+158% +$4.64M 0.02% 599
2019
Q3 		$1.96M Sell
13,567
-6,186
-31% -$839K ﹤0.01% 1121
2019
Q2 		$1.77M Sell
19,753
-4,954
-20% -$398K ﹤0.01% 1262
2019
Q1 		$2.16M Buy
24,707
+9,140
+59% +$1.01M 0.01% 1186
2018
Q4 		$2.19M Sell
15,567
-326
-2% -$55K 0.01% 1137
2018
Q3 		$4.06M Buy
15,893
+5,460
+52% +$1.51M 0.01% 908
2018
Q2 		$2.66M Buy
+10,433
New +$2.58M 0.01% 1169

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Two Sigma Advisers's KPTI Position: Q1 2026 in Review

Two Sigma Advisers sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 89,729 shares — an estimated $660K sold.

Two Sigma Advisers first reported a position in KPTI in Q2 2018 and held it in 26 quarters. The position peaked at $17.3M in Q3 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Two Sigma Advisers reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 89,729 Karyopharm Therapeutics shares in Q1 2026, an estimated $660K.
  • Two Sigma Advisers first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 26 quarters.
  • Two Sigma Advisers's Karyopharm Therapeutics position peaked at $17.3M in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.